Dual Binding Antibody Design via Amino Acid Variants
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing bispecific antibodies are complex, costly, and face challenges such as short half-life, immunogenicity, and low thermal stability, limiting their therapeutic potential due to the need for extensive protein engineering and manufacturing processes.
Innovation Solution
A method for generating polypeptides with dual binding specificity by identifying amino acid sequences that bind to a first antigen, introducing variants to create binding sites for a second antigen, and using high-throughput screening to select candidates that maintain binding affinity to both antigens, allowing for the production of antibodies that can target multiple epitopes simultaneously.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If traditional methods are used to produce bisspecific antibodies through biological or chemical means, then dual binding specificity is achieved, but production complexity and cost increase significantly
Solution Approach 1:
The patent introduces amino acid variants into the antigen-binding site of a monoclonal antibody before production, pre-configuring the antibody structure to enable dual binding specificity. This preliminary genetic modification eliminates the need for complex post-production engineering or hybridoma fusion techniques, thereby reducing production complexity while achieving bispecific functionality
Solution Approach 2:
The patent modifies the amino acid sequence parameters of the antibody's variable regions (VH and VL domains) by introducing specific variants at selected positions. These parameter changes in the protein structure enable the antibody to bind a second antigen while maintaining production simplicity through direct genetic engineering of the parent monoclonal antibody
2Adaptability or versatility
If extensive protein engineering is applied to create bispecific antibodies, then dual antigen binding is achieved, but manufacturing cost and process complexity increase
Solution Approach 1:
The desired dual binding capability is built into the antibody structure through preliminary introduction of amino acid variants during antibody design. This upfront genetic modification eliminates the need for complex multi-step protein engineering processes during manufacturing, such as hybridoma fusion or chemical conjugation, thereby simplifying production while achieving bispecific functionality
Solution Approach 2:
The patent applies amino acid variant introduction specifically at selected positions within the antigen-binding site (variable regions) rather than throughout the entire antibody structure. This localized modification approach achieves dual binding capability with minimal structural changes, reducing manufacturing complexity and cost compared to global protein engineering approaches
3Adaptability or versatility
If monoclonal antibodies are designed with dual binding specificity through variant introduction, then therapeutic potential is enhanced, but binding affinity to original antigen may be affected
Solution Approach 1:
The patent introduces amino acid variants at specifically selected positions within the antigen-binding site that are less critical for maintaining high-affinity binding to the original antigen. By targeting non-critical residues for modification, the antibody retains its binding affinity for the first antigen while gaining the ability to bind a second antigen, thus preserving therapeutic reliability
Solution Approach 2:
The patent carefully selects which amino acid parameters (residue positions and types) to modify in the variable regions, making controlled changes that enable dual binding while monitoring and maintaining binding affinity. The systematic approach to parameter modification ensures that therapeutic effectiveness is preserved while achieving enhanced versatility
Data Source
AI summary
Described herein are method of generating and uses of polypeptides with dual binding specificity, wherein the polypeptides contain a first binding-site for a first antigen and a second binding-site for a second antigen. The second binding-site comprises amino acid variants of native amino acid sequences of polypeptides that bind to the first antigen, wherein the variants do not abrogate binding to said first antigen. In one embodiment, polypeptides with dual binding specificity to PD1 and OX40 are disclosed herein. In another embodiment, polypeptides with dual binding specificity to PD1 and GITR are disclosed herein.